)
Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Sub-analyses from trials like LEADER (liraglutide) and REWIND (dulaglutide) have shown modest reductions in high-sensitivity C-reactive protein (hsCRP) and other inflammatory biomarkers among patients treated with these agents
Elsevier Health
[ 3 H] GSSG uptake assay in immunopurified ER SLC33A1 knockout HEK293T or Slc33a1 knockout KPK cells expressing EMC3-mScarlet-3xHA (ER-tag) complemented with a vector control or SLC33A1 cDNA were treated with 1 mM BSO for 48 hours prior for ER isolation
134 VisentinC.PellistriF.NatalelloA.VertemaraJ.BonanomiM.GattaE.et al (2017)
US$ 26.47
US$ 24.25
US$ 24.40
US$ 27.22
